Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOY-101 in Advanced Non-Neovascular Age-Related Macular Degeneration
NCT06087458Phase 2Active, not recruiting
- Sponsor
- Perceive Biotherapeutics
- Start
- Jun 2023
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 3
01
Overview
A Phase 2 trial of VOY-101 in geographic atrophy (GA), sponsored by Perceive Biotherapeutics. Started Jun 2023; status: active, not recruiting.
02
Drugs
VOY-101
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT06087458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087458.